GO:0051134 negative regulation of NK T cell activation: Immune Checkpoint Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0051134 describes any biological process that stops, prevents, or reduces the frequency, rate, or extent of natural killer T (NKT) cell activation.
• NKT cells are innate-like T lymphocytes that recognize glycolipid antigens presented by CD1d and rapidly produce cytokines such as IFN-gamma and IL-4.
• Negative regulation of NKT cell activation is critical for preventing excessive inflammation, autoimmunity, and tissue damage while preserving immune surveillance.
• Tumor-derived factors such as lactic acid, sialylated glycans, and cancer-associated fibroblasts can suppress NKT cell and NK cell activation, contributing to immune evasion.
• Key genes and pathways involved include CD1d, PD-1, TGF-beta, IL-10, and metabolic regulators such as LDHA.
• CRISPR knockout, knock-in, and overexpression models are essential tools for dissecting the molecular mechanisms that negatively regulate NKT cell activation.
Description
Natural killer T (NKT) cells are a specialized subset of T lymphocytes that bridge innate and adaptive immunity. Unlike conventional T cells, NKT cells recognize glycolipid antigens presented by the MHC class I-like molecule CD1d and can rapidly secrete large amounts of cytokines, including IFN-gamma and IL-4, upon activation. Because of their potent immunoregulatory functions, NKT cell activation must be tightly controlled to avoid excessive inflammation and autoimmunity. The Gene Ontology term GO:0051134, negative regulation of NK T cell activation, encompasses any process that stops, prevents, or reduces the frequency, rate, or extent of NKT cell activation. This term is essential for researchers studying immune tolerance, tumor immunology, and inflammatory diseases. Recent studies have shown that tumors exploit multiple mechanisms to suppress NKT cell and NK cell activation, including lactic acid production by tumor cells, sialylated glycan barriers, and decoy effects mediated by cancer-associated fibroblasts. Understanding these negative regulatory pathways is critical for developing novel immunotherapies. This article provides a comprehensive overview of GO:0051134, covering its definition, biological significance, key genes, disease associations, and state-of-the-art research methods including CRISPR-based models.
negative regulation of NK T cell activation At A Glance
| GO ID | GO:0051134 |
|---|---|
| GO term | negative regulation of NK T cell activation |
| Ontology | biological_process |
| Synonym | inhibition of NK T cell activation; negative regulation of NKT cell activation; downregulation of NK T cell activation |
| Major function | Suppression of NKT cell activation to prevent excessive inflammation and autoimmunity |
| Related cell type | Natural killer T (NKT) cells |
| Key receptors | CD1d, TCR, PD-1, NKG2D |
| Associated diseases | Cancer, autoimmune diseases, inflammatory disorders |
| Research methods | CRISPR knockout, knock-in, overexpression, single-cell RNA-seq, flow cytometry |
What Is GO:0051134?
GO:0051134, negative regulation of NK T cell activation, is defined as any biological process that stops, prevents, or reduces the frequency, rate, or extent of natural killer T cell activation. This includes molecular mechanisms such as inhibitory receptor signaling, cytokine-mediated suppression, metabolic restriction, and cell-cell interactions that dampen NKT cell responses. The term is a child of negative regulation of T cell activation and is specific to NKT cells, which are characterized by their CD1d-restricted antigen recognition and rapid cytokine production.
Why Is negative regulation of NK T cell activation Important in Cell Biology?
Negative regulation of NKT cell activation is essential for maintaining immune homeostasis and preventing immunopathology. NKT cells can produce both pro-inflammatory and anti-inflammatory cytokines, and their dysregulation is implicated in autoimmune diseases, cancer, and chronic inflammatory conditions. Understanding the mechanisms that restrain NKT cell activation provides insights into how tumors evade immune surveillance and how autoimmune responses can be controlled. For example, tumor-derived lactic acid blunts T and NK cell immunosurveillance, and sialylated CD43 forms a glyco-immune barrier that restrains antileukemic immunity. These findings highlight the therapeutic potential of targeting negative regulatory pathways to enhance anti-tumor immunity or to suppress autoimmunity.
• Prevents excessive cytokine release and systemic inflammation by NKT cells.
• Plays a role in tumor immune evasion, as tumors can suppress NKT and NK cell activation.
• Contributes to autoimmune disease pathogenesis when negative regulation fails.
• Influences the efficacy of immunotherapies such as anti-PD-1 treatment.
• Modulates metabolic pathways, including lactic acid production, that affect immune cell function.
• Involves cell-cell interactions with cancer-associated fibroblasts that act as decoys.
• Regulates the balance between Th1 and Th2 immune responses.
• Provides targets for CRISPR-based screens to identify novel immune checkpoints.
• Relevant to graft-versus-host disease and transplant tolerance.
• Key to understanding sex differences and age-related immune changes.
What Happens During negative regulation of NK T cell activation?
Inhibitory Receptor Signaling
In simple terms: Certain receptors on NKT cells act like brakes to stop them from becoming overactive.
NKT cell activation can be negatively regulated by inhibitory receptors such as PD-1, CTLA-4, and NKG2A. Engagement of these receptors by their ligands on tumor cells or antigen-presenting cells recruits phosphatases like SHP-1 and SHP-2, which dephosphorylate key signaling molecules in the TCR pathway, thereby dampening NKT cell activation. For instance, PD-1/PD-L1 interactions suppress T cell and NK cell activation, and blockade of this axis can restore anti-tumor immunity. Similarly, sialylated glycans on tumor cells can engage inhibitory Siglec receptors to restrain immune cell activation.
Cytokine-Mediated Suppression
In simple terms: Some cytokines tell NKT cells to calm down instead of attack.
Immunosuppressive cytokines such as TGF-beta and IL-10 can directly inhibit NKT cell activation. TGF-beta signaling in T cells induces Foxp3 expression and promotes regulatory T cell differentiation, which in turn suppresses NKT cell responses. IL-10, produced by regulatory T cells and macrophages, can inhibit antigen presentation and reduce NKT cell cytokine production. In the tumor microenvironment, cancer-associated fibroblasts and tumor-associated macrophages secrete these cytokines to suppress NKT and NK cell cytotoxicity.
Metabolic Restriction
In simple terms: Low oxygen, low nutrients, or waste products can tire out NKT cells and stop them from working.
Metabolic factors in the tumor microenvironment, such as lactic acid produced by tumor cells via LDHA, can blunt T and NK cell immunosurveillance. Lactic acid lowers intracellular pH and inhibits glycolysis and cytokine production in T and NK cells. Additionally, tryptophan depletion by indoleamine 2,3-dioxygenase (IDO) and arginine depletion by arginase can suppress NKT cell proliferation and function. These metabolic checkpoints represent important negative regulatory mechanisms.
Cell-Cell Contact and Decoy Effects
In simple terms: Other cells can act as decoys or shields to prevent NKT cells from reaching their targets.
Cancer-associated fibroblasts (CAFs) can serve as decoys that bind to NK cells and prevent them from engaging tumor cells, thereby suppressing NK cell anticancer cytotoxicity. Similar mechanisms may apply to NKT cells. Additionally, sialylated CD43 on leukemic cells forms a glyco-immune barrier that restrains antileukemic immunity by interfering with immune cell activation. These contact-dependent mechanisms represent a form of negative regulation of NKT cell activation.
Regulatory T Cell Suppression
In simple terms: Regulatory T cells act as peacekeepers that can shut down NKT cell attacks.
Regulatory T cells (Tregs) can suppress NKT cell activation through multiple mechanisms, including cell-cell contact, secretion of inhibitory cytokines (IL-10, TGF-beta), and consumption of IL-2. Tregs express high levels of CD25 and can deprive effector T cells and NKT cells of IL-2, leading to their apoptosis or anergy. In the tumor microenvironment, Tregs are often enriched and contribute to immune evasion by suppressing NKT cell activation.
Key Genes Involved in GO:0051134 negative regulation of NK T cell activation
The following genes and proteins are key players in the negative regulation of NKT cell activation, based on published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| CD1d | Antigen-presenting molecule for glycolipids to NKT cells | Target for modulating NKT cell activation |
| PDCD1 (PD-1) | Inhibitory receptor on T and NKT cells | Checkpoint blockade target |
| TGFB1 | Immunosuppressive cytokine | Promotes Treg differentiation and inhibits NKT cells |
| IL10 | Anti-inflammatory cytokine | Suppresses antigen presentation and NKT activation |
| LDHA | Lactate dehydrogenase A | Produces lactic acid that blunts T and NK cell immunosurveillance |
| CD43 (SPN) | Sialylated glycoprotein | Forms glyco-immune barrier restraining antileukemic immunity |
| FOXP3 | Master transcription factor for Tregs | Treg-mediated suppression of NKT cells |
| NKG2A (KLRC1) | Inhibitory receptor on NK and NKT cells | Binds HLA-E to inhibit activation |
| CTLA4 | Inhibitory receptor | Competes with CD28 for CD80/CD86 |
| HAVCR2 (TIM-3) | Inhibitory receptor | Suppresses T cell and NKT cell responses |
| LAG3 | Inhibitory receptor | Negatively regulates T cell activation |
| TIGIT | Inhibitory receptor | Competes with CD226 for CD155 |
| IL2RA (CD25) | High-affinity IL-2 receptor alpha chain | Treg-mediated IL-2 consumption |
| IDO1 | Indoleamine 2,3-dioxygenase | Depletes tryptophan, suppressing NKT cells |
| ARG1 | Arginase 1 | Depletes arginine, inhibiting NKT cell proliferation |
| SIGLEC7/9 | Sialic acid-binding immunoglobulin-like lectins | Inhibitory receptors engaging sialylated ligands |
| CD226 (DNAM-1) | Activating receptor | Competes with TIGIT for ligands |
How Is negative regulation of NK T cell activation Regulated?
The negative regulation of NKT cell activation is itself tightly regulated at multiple levels. Transcriptional regulation involves transcription factors such as Foxp3, which drives Treg development and function. Post-translational modifications, including phosphorylation and ubiquitination, control the stability and activity of inhibitory receptors. Metabolic regulation through mTOR signaling and the integrated stress response (ISR) can influence NKT cell responsiveness. For example, lactic acid produced by LDHA in tumor cells alters the metabolic environment and suppresses T and NK cell function. Additionally, the sialylation of cell surface proteins such as CD43 creates a glyco-immune barrier that restrains immune activation. These regulatory layers ensure that NKT cell activation is appropriately dampened to prevent immunopathology.
negative regulation of NK T cell activation and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| LDHA | Cancer immune evasion via lactic acid | LDHA knockout tumor cells co-cultured with NKT cells |
| CD43 (SPN) | Leukemia glyco-immune barrier | CD43 knockout leukemia cells in mouse models |
| PDCD1 (PD-1) | Cancer immunotherapy resistance | PD-1 knockout mice or CAR-NKT cells |
| TGFB1 | Autoimmunity and cancer | TGF-beta receptor knockout NKT cells |
| IL10 | Inflammatory bowel disease | IL-10 knockout mice |
Cancer Immune Evasion
Tumors employ multiple strategies to negatively regulate NKT cell activation, thereby evading immune destruction. Lactic acid produced by tumor cells via LDHA blunts T and NK cell immunosurveillance. Sialylated CD43 on leukemic cells forms a glyco-immune barrier that restrains antileukemic immunity. Cancer-associated fibroblasts act as decoys to suppress NK cell anticancer cytotoxicity in breast cancer. In pancreatic ductal adenocarcinoma, single-cell transcriptional dissection revealed an evolution of immunosuppressive microenvironment during metastasis. These mechanisms highlight the importance of understanding negative regulation of NKT cell activation for developing effective cancer immunotherapies.
Autoimmune Diseases
Defective negative regulation of NKT cell activation can lead to autoimmune diseases such as type 1 diabetes, multiple sclerosis, and inflammatory bowel disease. NKT cells can produce both pro-inflammatory and anti-inflammatory cytokines, and their dysregulation contributes to autoimmunity. For example, in non-obese diabetic (NOD) mice, NKT cell defects are associated with diabetes development. Therapies that enhance negative regulation of NKT cell activation, such as IL-10 or TGF-beta, are being explored for treating autoimmune conditions.
Inflammatory Disorders
Excessive NKT cell activation is implicated in inflammatory disorders such as asthma, atherosclerosis, and hepatitis. Negative regulation of NKT cell activation is crucial to prevent tissue damage. For instance, in concanavalin A-induced hepatitis, NKT cells play a pathogenic role, and their suppression can ameliorate liver injury. Understanding the molecular mechanisms that restrain NKT cell activation may lead to novel anti-inflammatory therapies.
Infectious Diseases
NKT cells are important for host defense against various pathogens, including bacteria, viruses, and fungi. However, excessive NKT cell activation can cause immunopathology. Negative regulation of NKT cell activation helps balance protective immunity and tissue damage. For example, in tuberculosis, NKT cells can both protect and contribute to lung pathology. Modulating negative regulatory pathways may improve outcomes in infectious diseases.
From negative regulation of NK T cell activation-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does gene X negatively regulate NKT cell activation? | CRISPR knockout of gene X in NKT cell line or primary NKT cells |
| Does a point mutation in gene Y affect its inhibitory function? | CRISPR point mutation knock-in in NKT cells |
| Does overexpression of gene Z suppress NKT cell activation? | Lentiviral overexpression in NKT cells |
| Does tagging gene W with a fluorescent protein affect its localization? | CRISPR knock-in of GFP tag |
| Which genes regulate NKT cell activation in a genome-wide manner? | CRISPR library screening in NKT cells |
| How does gene A affect NKT cell metabolism? | CRISPR knockout followed by metabolic assays |
How to Study the negative regulation of NK T cell activation Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Flow cytometry | Surface markers and intracellular cytokines | Quantify NKT cell activation |
| Single-cell RNA-seq | Transcriptomes of individual cells | Identify immunosuppressive pathways |
| CRISPR knockout screen | Gene knockouts that enhance activation | Discover negative regulators |
| Phosphoproteomics | Phosphorylation events | Map inhibitory signaling |
| ELISA | Cytokine secretion | Measure IFN-gamma and IL-4 |
| Metabolic assays | Glycolysis, oxidative phosphorylation | Assess metabolic restriction |
| Imaging | Cell-cell interactions | Visualize decoy effects |
Flow Cytometry and Activation Markers
Flow cytometry is a cornerstone method for studying NKT cell activation. Researchers can measure surface markers such as CD69, CD25, and CD137, as well as intracellular cytokines like IFN-gamma and IL-4. To study negative regulation, NKT cells can be stimulated with alpha-galactosylceramide (alpha-GalCer) in the presence or absence of inhibitory signals, and activation markers can be quantified. This method is widely used to assess the impact of CRISPR knockouts on NKT cell activation.
Single-Cell RNA Sequencing
Single-cell RNA sequencing (scRNA-seq) allows for the dissection of heterogeneous NKT cell populations and the identification of negative regulatory pathways. For example, single-cell profiling of esophageal squamous cell carcinoma revealed immune cell dynamics in response to chemo-immunotherapy. In pancreatic ductal adenocarcinoma, scRNA-seq illuminated the evolution of an immunosuppressive microenvironment during metastasis. These studies highlight how scRNA-seq can uncover genes and pathways that negatively regulate NKT cell activation.
CRISPR Screens
Genome-wide CRISPR knockout screens are powerful tools to identify negative regulators of NKT cell activation. By transducing NKT cells with a CRISPR library and stimulating them, researchers can select for cells with enhanced activation and then sequence the integrated guide RNAs to identify enriched knockouts. This approach has been used to discover novel immune checkpoints and metabolic regulators.
Proteomics and Phosphoproteomics
Mass spectrometry-based proteomics and phosphoproteomics can quantify changes in protein expression and signaling pathways following NKT cell activation. These methods can identify post-translational modifications that mediate negative regulation, such as phosphorylation of inhibitory receptors or ubiquitination of signaling intermediates.
How CRISPR Can Be Used to Study GO:0051134 negative regulation of NK T cell activation
Knockout
CRISPR knockout is used to delete genes suspected of negatively regulating NKT cell activation. For example, knocking out PDCD1 or TGFBR1 in NKT cells can reveal whether these genes suppress activation. Knockout models are also used in genome-wide screens to identify novel negative regulators. EDITGENE provides custom CRISPR knockout cell models for NKT cell research.
Point Mutation
CRISPR point mutation knock-in allows the introduction of specific amino acid changes to study the function of inhibitory receptors or signaling molecules. For instance, mutating phosphorylation sites in PD-1 or TGF-beta receptors can reveal their role in negative regulation. This approach is valuable for dissecting molecular mechanisms.
Knock-in
CRISPR knock-in can be used to tag endogenous proteins with fluorescent markers or epitope tags, enabling real-time tracking of their localization and interactions. For example, knocking in a GFP tag on CD1d or PD-1 allows visualization of these proteins in live NKT cells. Knock-in of reporter genes can also be used to monitor activation.
Overexpression
CRISPR overexpression models, often achieved by knocking in a strong promoter or using lentiviral vectors, can be used to study the effects of overexpressing negative regulators. For example, overexpressing IL-10 or TGF-beta in the tumor microenvironment can suppress NKT cell activation. EDITGENE offers overexpression cell models for such studies.
How EDITGENE Supports negative regulation of NK T cell activation Research
Researchers studying negative regulation of NK T cell activation-related genes often need to determine whether a candidate gene is causally involved in suppressing NKT cell responses. EDITGENE provides a comprehensive suite of CRISPR-based services to accelerate this research, from knockout and point mutation to knock-in and overexpression models, as well as library screening and bioinformatics support.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of NK T cell activation research.
Frequently Asked Questions About negative regulation of NK T cell activation
What is GO:0051134?
GO:0051134 is the Gene Ontology term for negative regulation of NK T cell activation, defined as any process that stops, prevents, or reduces the frequency, rate, or extent of natural killer T cell activation.
What are NKT cells?
NKT cells are a specialized subset of T lymphocytes that recognize glycolipid antigens presented by CD1d and rapidly produce cytokines such as IFN-gamma and IL-4.
What genes are involved in negative regulation of NKT cell activation?
Key genes include PDCD1 (PD-1), TGFB1, IL10, LDHA, CD43 (SPN), FOXP3, and SIGLEC7/9.
How do tumors suppress NKT cell activation?
Tumors can suppress NKT cell activation through lactic acid production, sialylated glycan barriers, cancer-associated fibroblast decoys, and immunosuppressive cytokines.
What diseases are associated with defective negative regulation of NKT cell activation?
Autoimmune diseases, inflammatory disorders, and cancer immune evasion are associated with dysregulation of NKT cell activation.
What research methods are used to study negative regulation of NKT cell activation?
Flow cytometry, single-cell RNA-seq, CRISPR screens, phosphoproteomics, and metabolic assays are commonly used.
How can CRISPR be used to study negative regulation of NKT cell activation?
CRISPR knockout, point mutation, knock-in, and overexpression models allow researchers to dissect the function of specific genes in NKT cell activation.
What is the role of LDHA in NKT cell activation?
LDHA produces lactic acid, which blunts T and NK cell immunosurveillance, thereby negatively regulating their activation.
What is the role of CD43 in immune evasion?
Sialylated CD43 forms a glyco-immune barrier that restrains antileukemic immunity, contributing to negative regulation of immune cell activation.
How does PD-1 negatively regulate NKT cell activation?
PD-1 is an inhibitory receptor that, upon engagement with PD-L1, recruits phosphatases to dampen TCR signaling, thereby suppressing NKT cell activation.
Conclusion
GO:0051134, negative regulation of NK T cell activation, is a critical biological process that maintains immune homeostasis and prevents immunopathology. Dysregulation of this process contributes to cancer immune evasion, autoimmune diseases, and inflammatory disorders. Key genes such as LDHA, CD43, PD-1, TGF-beta, and IL-10 play central roles in suppressing NKT cell activation. Advances in CRISPR-based models and single-cell technologies are accelerating the discovery of novel negative regulators. EDITGENE provides essential tools and services to support this research, from knockout and knock-in models to library screening and bioinformatics.
References
- 1. Brand A et al.. 2016. LDHA-Associated Lactic Acid Production Blunts Tumor Immunosurveillance by T and NK Cells.. Cell Metab 24(5):657-671 PMID: 27641098
- 2. Ji G et al.. 2024. Single-cell profiling of response to neoadjuvant chemo-immunotherapy in surgically resectable esophageal squamous cell carcinoma.. Genome Med 16(1):49 PMID: 38566201
- 3. Chung J et al.. 2026. Sialylated CD43 forms a glyco-immune barrier that restrains antileukemic immunity.. Science 392(6794):eady5196 PMID: 41955354
- 4. Ben-Shmuel A et al.. 2025. Cancer-Associated Fibroblasts Serve as Decoys to Suppress NK Cell Anticancer Cytotoxicity in Breast Cancer.. Cancer Discov 15(6):1247-1269 PMID: 40052789
- 5. Liu X et al.. 2025. Single-cell transcriptional dissection illuminates an evolution of immunosuppressive microenvironment during pancreatic ductal adenocarcinoma metastasis.. Signal Transduct Target Ther 10(1):182 PMID: 40484878
- 7. Shi T et al.. 2022. DKK1 Promotes Tumor Immune Evasion and Impedes Anti-PD-1 Treatment by Inducing Immunosuppressive Macrophages in Gastric Cancer.. Cancer Immunol Res 10(12):1506-1524 PMID: 36206576
